雄甾-4-烯-17-酮 | 5225-35-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雄甾-4-烯-17-酮
• 英文名称: androst-4-en-17-one
• 英文别名: 3-deoxyandrostenedione；androst-5-en-17-one；androsten-(4)-one-(17)；Androsten-(4)-on-(17)；17-Oxo-androsten-(4)；(8R,9S,10R,13S,14S)-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• CAS: 5225-35-4
• 化学式: C₁₉H₂₈O
• 分子量: 272.431
• InChiKey: MNOAOFLIFDRILH-QAGGRKNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  雄甾-4-烯-17-酮 在 potassium permanganate 、 溶剂黄146 作用下， 生成 雄烯二酮
  参考文献：
  名称：

  US2397424

  摘要：

  公开号：
• 作为产物：
  描述：

  5-androsten-17-one 在 丙醇 、 sodium 作用下， 生成 雄甾-4-烯-17-酮
  参考文献：
  名称：

  US2397424

  摘要：

  公开号：

文献信息

• Insights into the Synthesis of Steroidal<i>A</i>-Ring Olefins
  作者：Carla L. Varela、Fernanda M. F. Roleira、Saul C. P. Costa、Alexandra S. C. T. Pinto、Ana I. O. S. Martins、Rui A. Carvalho、Natércia A. Teixeira、Georgina Correia-da-Silva、Elisiário Tavares-da-Silva

  DOI：10.1002/hlca.201300082

  日期：2014.1

  The classical synthesis, followed by purification of the steroidal A‐ring Δ1‐olefin, 5α‐androst‐1‐en‐17‐one (5), from the Δ1‐3‐keto enone, (5α,17β)‐3‐oxo‐5‐androst‐1‐en‐17‐yl acetate (1), through a strategy involving the reaction of Δ1‐3‐hydroxy allylic alcohol, 3β‐hydroxy‐5α‐androst‐1‐en‐17β‐yl acetate (2), with SOCl2, was revisited in order to prepare and biologically evaluate 5 as aromatase inhibitor

  经典合成，随后是甾体的纯化甲形环Δ 1烯烃，5 α -雄甾-1-烯-17-酮（5）中，从Δ 1 -3酮烯酮，（5 α，17 β）-3-氧代-5-雄甾-1-烯-17-基乙酸酯（1），通过涉及Δ的反应的策略1 -3-羟基烯丙基醇，3- β羟基-5- α -雄甾-1-烯-17- β基乙酸酯（2）中，用的SOCl 2，是为了重新制备和生物学评价5作为乳腺癌的芳香化酶抑制剂。令人惊讶地，随后策略也得到同分异构的Δ 2烯烃6作为副产物，这只能NMR分析的基础上被检测到。纯化和检测程序的优化使我们可以达到化合物5生物学检测所需的96％纯度。相同的合成策略应用于，使用Δ 4 -3-酮烯酮，3-氧代雄甾-4-烯-17- β -基乙酸甲酯（8），作为起始原料，以制备有效的芳香酶抑制剂Δ 4烯烃，雄甾‐4‐en‐17‐一（15）。出乎意料的是，另一种芳香化酶抑制剂Δ3,5形成了二烯，rost-3,5-dien-
• 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE
  申请人：Kuhnke Joachim

  公开号：US20100292184A1

  公开（公告）日：2010-11-18

  The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO 2 R, in which R is hydrogen or C 1 -C 4 -alkyl, R 1 , R 2 are each independently hydrogen or methyl, or R 1 and R 2 together form methylene or are omitted with formation of a double bond between C 1 and C 2 , R 4 is hydrogen or halogen, furthermore either: R 6a , R 6b together form methylene or 1,2-ethanediyl or R 6a is hydrogen and R 6b is selected from the group comprising hydrogen, methyl and hydroxymethylene, and R 7 is selected from the group comprising hydrogen, C 1 -C 4 -alkyl, C 2 -C 3 -alkenyl and cyclopropyl, or: R 6a hydrogen and R 6b and R 7 together form methylene or are omitted with formation of a double bond between C 6 and C 7 or: R 6a is methyl and R 6b and R 7 are omitted with formation of a double bond between C 6 and C 7 , R 15 , R 16 are hydrogen or together form methylene, R 17 is selected from the group comprising hydrogen, C 1 -C 4 -alkyl and allyl, and moreover comprise their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts, with the proviso that particular compounds are excluded.

  本发明的17β-氰基-19-雄甾-4-烯衍生物具有孕激素活性。它们具有通用化学式1，其中Z选自包括O、两个氢原子、NOR和NNHSO2R的基团，其中R是氢或C1-C4烷基，R1、R2各自独立地为氢或甲基，或者R1和R2共同形成亚甲基或省略并在C1和C2之间形成双键，R4是氢或卤素，此外：R6a、R6b共同形成亚甲基或1,2-乙二基或R6a为氢，R6b选自包括氢、甲基和羟甲基，R7选自包括氢、C1-C4烷基、C2-C3烯基和环丙基，或：R6a为氢，R6b和R7共同形成亚甲基或省略并在C6和C7之间形成双键或：R6a为甲基，R6b和R7省略并在C6和C7之间形成双键，R15、R16为氢或共同形成亚甲基，R17选自包括氢、C1-C4烷基和烯丙基，此外还包括它们的溶剂化合物、水合物、立体异构体、对映异构体和盐，但特定的化合物除外。
• Exploring new chemical functionalities to improve aromatase inhibition of steroids
  作者：Carla L. Varela、Cristina Amaral、Georgina Correia-da-Silva、Saul C. Costa、Rui A. Carvalho、Giosuè Costa、Stefano Alcaro、Natércia A.A. Teixeira、Elisiário J. Tavares-da-Silva、Fernanda M.F. Roleira

  DOI：10.1016/j.bmc.2016.04.056

  日期：2016.6

  In this work, new potent steroidal aromatase inhibitors both in microsomes and in breast cancer cells have been found. The synthesis of the 3,4-(ethylenedioxy)androsta-3,5-dien-17-one (12), a new steroid containing a heterocycle dioxene fused in the A-ring, led to the discovery of a new reaction for which a mechanism is proposed. New structure-activity relationships were established. Some 5β-steroids

  在这项工作中，已经发现了微粒体和乳腺癌细胞中新的有效的甾体芳香化酶抑制剂。3,4-（亚乙二氧基）androsta-3,5-dien-17-one（12）的合成是一种新的甾族化合物，其中含有杂环二恶烯稠合在A环中，导致发现了新的反应，提出了一种机制。建立了新的结构-活性关系。一些5β-类固醇（例如化合物4β，5β-环氧雄烷-17-一（9））显示出芳香化酶抑制活性，因为它们采用与芳香化酶天然底物雄烯二酮类似的A环构型。此外，还公开了增加平面度的新化学特征，特别是3α，4α-环丙烷环，如3α，4α-亚甲基-5α-雄烷-17-一（5）（IC50 =0.11μM）和Δ（9 -11）在C环中的双键，如androsta-4,9（11）-diene-3，17-二酮（13）（IC50 =0.25μM）。此外，诱导拟合对接（IFD）模拟和新陈代谢部位（SoM）预测有助于解释该酶中新的有效甾体芳香酶抑制剂的识别
• Role of Hydrophilic Interaction in Binding of Hydroxylated 3-Deoxy C₁₉ Steroids to the Active Site of Aromatase
  作者：Mitsuteru Numazawa、Keiko Yamada、Syoko Nitta、Chika Sasaki、Kanae Kidokoro

  DOI：10.1021/jm010282t

  日期：2001.11.1

  relationship of a novel class of aromatase inhibitors, C(19) steroids having no oxygen function at C-3, we tested aromatase inhibition activity of polar diol compounds 4,19-dihydroxyandrost-5-en-17-ones (25 and 27) and 6,19-dihydroxyandrost-4-en-17-ones (36 and 37). 4alpha,19-Diol 25 was synthesized from tert-butyldimethylsilyoxyandrost-4-ene steroid (9) through its OsO(4) oxidation, giving the 4alpha,5alpha-dihydroxy

  作为我们对一类新型芳香酶抑制剂C（19）类固醇在C-3处无氧功能的构效关系的研究的一部分，我们测试了极性二醇化合物4,19-dihydroxyandrost-5-的芳香酶抑制活性en-17-ones（25和27）和6,19-dihydroxyandrost-4-en-17-ones（36和37）。由叔丁基二甲基甲硅烷氧基雄烷-4-烯类固醇（9）通过其OsO（4）氧化合成4alpha，19-Diol 25，得到4alpha，5alpha-dihydroxy衍生物12作为关键反应。乙酰化5beta，6alpha-dihydroxy-19-acetate 30及其5alpha，6beta-analogue 31，然后用SOCl（2）脱水和碱性羟基化分别得到6alpha，19-二醇36和6beta-异构体37。化合物（25）的C-4处的羟基的立体化学和化合物36和37的C-6处的羟基的立体化学分别基于（1）H
• Design, synthesis, and antitumor activity evaluation of steroidal oximes
  作者：Ana R. Gomes、Ana S. Pires、Ana M. Abrantes、Ana C. Gonçalves、Saul C. Costa、Carla L. Varela、Elisiário T. Silva、Maria F. Botelho、Fernanda M.F. Roleira

  DOI：10.1016/j.bmc.2021.116360

  日期：2021.9

  Steroidal compounds were proven to be efficient drugs against several types of cancer. Oximes are also chemical structures frequently associated with anticancer activity. The main goal of this work was to combine the two referred structures by synthesizing steroidal oximes and evaluating them in several cancer cell lines. Compounds (17E)-5α-androst-3-en-17-one oxime (3,4 – OLOX), (17E)-3α,4α-epoxy

  甾体化合物被证明是对抗多种癌症的有效药物。肟也是经常与抗癌活性相关的化学结构。这项工作的主要目标是通过合成甾体肟并在几种癌细胞系中对其进行评估来组合这两种结构。化合物 (17 E ) -5α-androst -3-en-17-one 肟 ( 3,4 – OLOX ), (17 E )-3α,4α-epoxy-5α-androstan-17-one 肟 ( 3,4 – EPOX ), (17 E )-androst-4-en-17-one 肟 ( 4,5 – OLOX ) 和 (17 E )-4α,5α-epoxyandrostan-17-one 肟 ( 4,5 – EPOX) 被合成并在四种人类癌细胞系中评估它们的细胞毒性，即结肠直肠腺癌 (WiDr)、非小细胞肺癌 (H1299)、前列腺癌 (PC3) 和肝细胞癌 (HepG2)。还使用了人类非肿瘤细胞系 CCD841 CoN（正常结肠细